Substance / Medication

Malathion

Overview

Active Ingredient
malathion
RxNorm CUI
6606

Indications

Pediculus humanus capitis Malathion lotion is indicated for patients infected with(head lice and their ova) of the scalp hair.

Labeler: Sun Pharmaceutical Industries, Inc.Updated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Malathion lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. Malathion lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Female reproductive toxicity after exposure to malathion or diazinon: a systematic review of rodent and human studies.
Barbosa Indiamara Guesser, Lazzari Virgínia Meneghini, Araújo Leite Gabriel Adan · Crit Rev Toxicol · 2025
PMID: 40904231Meta-Analysis
Malathion or diazinon exposure and male reproductive toxicity: a systematic review of studies performed with rodents.
Delorenzi Schons Daniel, Leite Gabriel Adan Araújo · Crit Rev Toxicol · 2023
PMID: 37922518Meta-Analysis
A global systematic review of the concentrations of Malathion in water matrices: Meta-analysis, and probabilistic risk assessment.
Vasseghian Yasser, Dragoi Elena-Niculina, Almomani Fares et al. · Chemosphere · 2022
PMID: 34742763Meta-Analysis
A global systematic review, meta-analysis and health risk assessment on the quantity of Malathion, Diazinon and Chlorpyrifos in Vegetables.
Kermani Majid, Dowlati Mohsen, Gholami Mitra et al. · Chemosphere · 2021
PMID: 33418228Meta-Analysis
Carcinogenicity and mutagenicity of malathion and its two analogues: a systematic review.
Bastos Priscilla Luna, Bastos Alyne Fernanda Tôrres de Lima, Gurgel Aline do Monte et al. · Cien Saude Colet · 2020
PMID: 32785560Meta-Analysis
Effects of exposure to malathion on blood glucose concentration: a meta-analysis.
Ramirez-Vargas Marco Antonio, Flores-Alfaro Eugenia, Uriostegui-Acosta Mayrut et al. · Environ Sci Pollut Res Int · 2018
PMID: 29235025Meta-Analysis
A protective effect of vitamin E and selenium in ameliorating the immunotoxicity of malathion in chicks.
Sodhi S, Sharma A, Brar R S · Vet Res Commun · 2006
PMID: 17139545RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Malathion (substance)
SNOMED CT
87205003
UMLS CUI
C0024547
RxNorm CUI
6606
Labeler
Sun Pharmaceutical Industries, Inc.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.